血清癌抗原19-9水平对胰腺癌可切除性判断的临床意义

The role of preoperative CA19-9 level in predicting resectability of pancreatic cancer

目的探讨血清癌抗原19—9（CA19—9）水平在胰腺癌可切除性判断中的应用价值。方法采用放射免疫法检测胰腺癌患者血清CA19—9的表达，通过接受者操作特征（ROC）曲线分析确定最佳分界点，通过ROC曲线下面积分析血清CA19—9水平对胰腺癌可切除性判断的临床应用价值。结果可切除性胰腺癌患者CA19~9的水平为（313．6±515．5）kU／L，明显低于不可切除患者的（852．1±865．1）ku／L（P=0．00）。根据接受者操作特性曲线，血清CA19—9对胰腺癌可切除性判断的最佳分界点为312．1kU／L，其灵敏度为56．6％，特异度为73．3％，ROC曲线下面积0．67。结论血清CA19-9水平可作为辅助性手段应用于胰腺癌可切除性的判断。

Objective To study the role of preoperative CA19-9 level in predicting resectability of pancreatic cancer. Methods Preoperative CA19-9 levels were determined by radioimmunoassay. The receiver operating characteristic curve was used to determine the cut-off point. The clinical value of the level of CA19-9 as a predictive marker of resectability was evaluated by the area under curve. Results The preoperative CA19-9 levels in the resectable group was （313.6±515.5） kU/L, which was significantly lower than （852.1± 865.1） kU/L in the unresectable group （P〈0. 001）. The cut-off point of CA19-9 for predicting pancreatic cancer resectablility was 312.1 kU/L, which had a sensitivity of 56.6% and a specificity of 73.3%. The area under curve was 0.67. Conclusions The preoperative CA19-9 level may be used to predict resectability of pancreatic cancer.